Artelo Biosciences (ARTL) announced details of a strategic partnership with BioAI company ScienceMachine to accelerate the development of its fatty acid-binding protein 5, or FABP5, inhibitor platform. ScienceMachine’s platform, which leverages AI agent technology, is built to interrogate large biological datasets. The partnership is harnessing ScienceMachine’s proprietary AI technology to analyze Artelo’s large internal FABP datasets and identify biological insights, including new mechanisms and therapeutic opportunities for FABP5 inhibitors, particularly ART26.12, the company’s first FABP5 inhibitor to begin clinical studies.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL:
- Artelo Biosciences announces publication of article on ART26.12
- Artelo Biosciences files to sell 9.82M shares of common stock for holders
- Artelo Biosciences regains compliance with Nasdaq
- 3 Penny Stocks to Watch Now, 3/31/26
- Artelo Biosciences Soars 230% on Obesity Push — Why Is ARTL Stock Now Crashing?